DuChemBIOLtd Past Earnings Performance
Past criteria checks 3/6
DuChemBIOLtd has been growing earnings at an average annual rate of 99.8%, while the Medical Equipment industry saw earnings growing at 22.8% annually. Revenues have been growing at an average rate of 2.6% per year. DuChemBIOLtd's return on equity is 18.6%, and it has net margins of 22.5%.
Key information
99.82%
Earnings growth rate
98.97%
EPS growth rate
| Medical Equipment Industry Growth | 22.66% |
| Revenue growth rate | 2.61% |
| Return on equity | 18.59% |
| Net Margin | 22.45% |
| Last Earnings Update | 31 Dec 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How DuChemBIOLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 24 | 35,601 | 7,994 | 5,704 | 0 |
| 31 Dec 23 | 34,695 | 4,001 | 4,921 | 205 |
Quality Earnings: A176750 has high quality earnings.
Growing Profit Margin: A176750's current net profit margins (22.5%) are higher than last year (11.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if A176750's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare A176750's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.
Earnings vs Industry: A176750 earnings growth over the past year (99.8%) exceeded the Medical Equipment industry -0.2%.
Return on Equity
High ROE: A176750's Return on Equity (18.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/12 09:22 |
| End of Day Share Price | 2025/05/12 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DuChemBIO Co.,Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jongsun Park | Eugene Investment & Securities Co Ltd. |